Protocol Ledger

NCT06321302 · Phase II · RECRUITING

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Interventional Phase II clinical trial protocol NCT06321302 sponsored by Boehringer Ingelheim in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-15 Enrollment: 175 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06321302
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)175 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06321302
Protocol FieldVerified Registry Value
NCT IdentifierNCT06321302
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment175 participants (ESTIMATED)
Registered Start Date2024-05-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06321302
Hospital Research SiteLocationSite Profile
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->
The Retina PartnersEncino, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI